Prostate-specific antigen kallikrein: From prostate cancer to cardiovascular system

European Heart Journal

Volumn 30, Issue 10, 2009, Pages 1169-1170

  Patan, Salvatore ^a   Marte, Filippo ^a  

^a Via Cattafi ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DISEASE ASSOCIATION; HEART MUSCLE CELL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

HUMANS; MYOCARDIAL INFARCTION; PROSTATE-SPECIFIC ANTIGEN;

EID: 66249096006     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp135     Document Type: Article

References (40)

1. Watt KWK, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
2. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214:317-322.
3. Crook M, Preston K, Lancaster I. Serum prostatic specific-antigen concentrations in acute myocardial infarction. Clin Chem 1997;43:1670.
4. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
5. Schifman RB, Ahmann FR, Elvick A, Ahmann M, Coulis K, Brawer MK. Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared. Clin Chem 1987;33:2086-2088.
6. Hagood PG, Parra RO, Rauscher JA. Nontraumatic evaluation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass. J Urol 1994;152:2043-2045.
7. Kiran PR. Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy? Aust Fam Physician 2001;30:458-460. Review.
8. Koller-Strametz J, Fritzer M, Gwechenberger M, Geppert A, Heinz G, Haumer M, Koreny M, Maurer G, Siostrzonek P. Elevation of prostate-specific markers after cardiopulmonary resuscitation. Circulation 2000;102:290-293.
9. Graves HC. Nonprostatic sources of prostate-specific antigen: a steroid hormone dependent phenomenon? Clin Chem 1995;41:7-9.
10. Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995;41:54-58.
11. Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-79.
12. Charlesworth MC, Young CY, Miller VM, Tindall DJ. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl 1999;20:220-229.
13. Rittenhouse HG, FinlayJA, Mikolajczyk SD, Partin AW. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275- 368.
14. Tepper SL, Jagirdar J, Heath D, Geller SA. Homology between the female paraurethral (Skene's) glands and the prostate. Arch Pathol Lab Med 1984;108:423-425.
15. Bourgeois L, Brillard-Bourdet M, Deperthes D, Juliano MA, Juliano L, Tremblay RR, Dube JY, Gauthier F. Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2. J Biol Chem 1997;272:29590-29595.
16. Frenette G, Tremblay RR, Lazure C, Dube JY. Prostatic kallikrein (hk2), but not prostate-specific antigen (hk3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 1997;71:897-899.
17. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer 1999;81: 438-442.
18. Balbay MD, Juang P, Ilansa N, Williams S, McConkey D, Fidler IJ, Pettaway CA. Stable transfection of human prostate cancer cell line PC-3 with prostate specific antigen induces apoptosis both in vivo and in vitro. Proc Am Assoc Cancer Res 1999; 40:225-226 (Abstract).
19. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999;91:1635-1640.
20. Heidtmann HH, Nettelbeck DM, Mingels A,Jager R, Welker HG, Kontermann RE. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 1999;81:1269-1273.
21. Cohen P, Graves HCB, Peehl DM, Kamarei M, Guidice LC, Rosenfeld RD. Prostate-specific antigen (PSA) is an insulinlike growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1991;73:401-407.
22. Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1998;17:383-390.
23. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, Hsiung HM, Becker GW, Neubauer BL Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 1999;91:1663-1669.
24. Li Q, Ceylan-Isik AF, Li J, Ren J. Deficiency of insulin-like growth factor 1 reduces sensitivity to aging-associated cardiomyocyte dysfunction. Rejuvenation Res 2008; 11:725-733.
25. Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen Lø. Insulin-like growth factor-I as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol 2009;160:25-31.
26. Rota M, Padin-Iruegas ME, Misao Y, De Angelis A, Maestroni S, Ferreira-Martins J, Fiumana E, Rastaldo R, Arcarese ML, Mitchell TS, Boni A, Bolli R, Urbanek K, Hosoda T, Anversa P, Leri A, Kajstura J. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res 2008;103:107-116.
27. Killian CS, Corral DA, Kawinski AM, Hsiung HM, Becker GW, Neubauer BL. Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 1999;91:1663-1669.
28. Sovari AA, Morita N, Weiss JN, Karagueuzian HS. Serum transforming growth factor-beta1 as a risk stratifier of sudden cardiac death. Med Hypotheses 2008; 71:262-265.
29. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 2008;103: 485-492.
30. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels.J Natl Cancer Inst 2008;100:1511-1518.
31. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007;67: 924-932.
32. Berent R, Auer J, Porodko M, Lamm G, Weber T, Wimmer E, Seier J, Aspöck G, Eber B. Influence of cardiopulmonary resuscitation on levels of tumour markers. Eur J Cancer Care (Engl) 2006;15:252-256.
33. Koreny M, Koller-Strametz J, Geppert A, Delle Karth G, Heinz G, Maurer G, Siostrzonek P. Elevation of prostatic markers following cardiogenic shock. Intensive Care Med 2001;27:447.
34. Patane S, Marte F. Paroxysmal ventricular tachycardia and paroxysmal atrial fibrillation associated with subclinical hyperthyroidism, chronic renal failure and elevation of prostate-specific antigen during acute myocardial infarction. Int J Cardiol 2008. Published online ahead of print 21 August 2008.
35. Patanè S, Marte F, Di Bella G, Ciccarello G. Changing axis deviation and elevation of prostate-specific antigen during acute myocardial infarction. Int J Cardiol 2008. Published online ahead of print 25 June 2008.
36. Patanè S, Marte F, Di Bella G, Ciccarello G. Changing axis deviation, paroxysmal atrial fibrillation and elevation of prostate-specific antigen during acute myocardial infarction. Int J Cardiol 2008. Published online ahead of print 8 August 2008.
37. Patane S, Marte F. Paroxysmal atrial fibrillation during acute myocardial infarction associated with subclinical hyperthyroidism, severe three vessels coronary artery disease and elevation of prostate-specific antigen after TURP. IntJ Cardiol 2008. Published online ahead of print 8 August 2008.
38. Patanè S, Marte F, Sturiale M, Grassi R, Patanè F. Significant coronary artery disease associated with coronary artery aneurysm and elevation of prostatespecific antigen during acute myocardial infarction. Int J Cardiol 2009. Published online ahead of print 12 January 2009.
39. Patanè S, Marte F. Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario. Int J Cardiol 2009. Published online ahead of print 21 January 2009.
40. Patanè S, Marte F. Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going ? Int J Cardiol 2009. Published online ahead of print 30 January 2009.